natgillin/translations-raw huggingface dataset:
There are insufficient data to support the 100 mg dose for longer than 35 days of treatment.
Ni dovolj podatkov, ki bi podpirali več kot 35-dnevno zdravljenje z odmerkom 100 mg.
A decision must be made whether to discontinue breast-feeding or to discontinue/abstain from Ecalta therapy taking into account the benefit of breast-feeding for the child and the benefit of therapy for the woman.
Odločiti se je treba med prenehanjem dojenja ali prenehanjem/prekinitvijo zdravljenja z zdravilom ECALTA, pri čemer je treba pretehtati koristi dojenja za otroka in koristi zdravljenja za mater.
Less than 1% of the administered radioactive dose was excreted in the urine, indicating negligible renal clearance.
Manj kot 1 % danega radioaktivnega odmerka se je izločil v urinu, kar kaže na zanemarljiv ledvični očistek.
Do not use ECALTA - if you are allergic to anidulafungin, other echinocandins (e.g.caspofungin acetate), or any of the other ingredients of this medicine (listed in section 6).
Ne uporabljajte zdravila ECALTA - če ste alergični na anidulafungin, druge ehinokandine (npr. kaspofunginijev acetat) ali katerokoli sestavino tega zdravila (navedeno v poglavju 6).
ECALTA is not recommended during pregnancy unless the benefit to the mother clearly outweighs the potential risk to the foetus.
Uporaba zdravila ECALTA med nosečnostjo ni priporočljiva, razen če koristi za mater upravičujejo potencialno tveganje za plod.
Not relevant.
Podatek ni pomemben.
What ECALTA is and what it is used for
Kaj je zdravilo ECALTA in za kaj ga uporabljamo
Of note, in vitro studies do not fully exclude possible in vivo interactions.
Omeniti pa je treba, da študije in vitro možnih interakcij in vivo ne izključujejo v celoti.
In the presence of ECALTA, fungal cells have incomplete or defective cell walls, making them fragile or unable to grow.
Celice glivic, izpostavljene zdravilu ECALTA, imajo nepopolno ali okvarjeno celično steno, zato so krhke in ne morejo rasti.
Patients who received at least one dose of study medicinal products and who had a positive culture for Candida species from a normally sterile site before study entry were included in the modified intentto-treat (MITT) population.
Bolniki, ki so dobili vsaj en odmerek preskušanega zdravila in so imeli pozitivno kulturo za vrste Candida z normalno sterilnega mesta pred vstopom v preskušanje, so bili vključeni v modificirano populacijo z-namenom-zdravljenja (MITT - Modified Intention To Treat).
Pharmacotherapeutic group: - Antimycotics for systemic use, other antimycotics for systemic use.ATC code: JO2AX06
Farmakoterapevtska skupina: antimikotiki za sistemsko zdravljenje, drugi antimikotiki; oznaka ATC: J02AX06
Available pharmacodynamic/toxicological data in animals have shown excretion of anidulafungin in milk.
Razpoložljivi farmakodinamični/toksikološki podatki pri živalih kažejo na izločanje anidulafungina v mleko.
Isolates with mutations in the hot spot regions of the target gene have been associated with clinical failures or breakthrough infections.
Izolati z mutacijami na žariščnih območjih tarčnega gena so bili povezani s klinično neuspešnostjo ali izbruhi okužbe.
If you forgot to use ECALTA
Če ste pozabili uporabiti zdravilo ECALTA
The following table includes, the all-causality adverse reactions (MedDRA terms) from 840 subjects receiving 100 mg anidulafungin with frequency corresponding to very common (≥1/10), common (1/100 to <1/10), uncommon (1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000) and from spontaneous reports with frequency not known (cannot be estimated from the available data).
Naslednja preglednica vsebuje neželene učinke zaradi vseh vzrokov (MedDRA izrazi) pri 840 preskušancih, ki so prejemali 100 mg anidulafungina, s pogostnostjo: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100), redki (≥ 1/10.000 do < 1/1.000), zelo redki (< 1/10.000), in iz spontanih poročil s pogostnostjo 'neznana' (ni mogoče oceniti iz razpoložljivih podatkov).
Rats were dosed with anidulafungin at three dose levels and anaesthetised within one hour using a combination of ketamine and xylazine.
Podgane so dobivale anidulafungin v treh ravneh odmerkov in bile v roku ene ure anestezirane s kombinacijo ketamina in ksilazina.
Plasma concentrations of anidulafungin in healthy men and women were similar.
Koncentracija anidulafungina v plazmi zdravih moških in žensk je podobna.
If these reactions occur, anidulafungin should be discontinued and appropriate treatment administered.
Če se pojavi takšna reakcija, je treba z uporabo anidulafungina prekiniti in uvesti ustrezno zdravljenje.
Approximately 30% of the administered radioactive dose was eliminated in the faeces over 9 days, of which less than 10% was intact drug.
Približno 30 % danega radioaktivnega odmerka se je izločilo v blatu v 9 dneh, od tega je bilo manj kot 10 % nespremenjenega zdravila.
Anidulafungin has a predominant elimination half-life of approximately 24 hours that characterizes the majority of the plasma concentration-time profile, and a terminal half-life of 40-50 hours that characterises the terminal elimination phase of the profile.
Anidulafungin ima prevladujoč razpolovni čas izločanja približno 24 ur, ki opredeljuje glavnino profila koncentracije v plazmi v odvisnosti od časa in terminalni razpolovni čas 40-50 ur, ki opredeljuje terminalno izločevalno fazo tega profila.
The efficacy of ECALTA has only been evaluated in a limited number of neutropenic patients (see section 5.1).
Učinkovitost zdravila ECALTA je bila ocenjena le pri omejenem številu bolnikov z nevtropenijo (glejte poglavje 5.1).
Other medicines and ECALTA
Druga zdravila in zdravilo ECALTA
ECALTA contains the active substance anidulafungin and is prescribed in adults to treat a type of fungal infection of the blood or other internal organs called invasive candidiasis.
Zdravilo ECALTA vsebuje učinkovino anidulafungin in se uporablja pri odraslih za zdravljenje posebne vrste glivične okužbe krvi ali drugih notranjih organov, imenovane invazivna kandidoza.
Anidulafungin treatment prolonged survival and also reduced the organ burden of Candida species, when determined at intervals from 24 to 96 hours after the last treatment.
Zdravljenje z anidulafunginom je podaljšalo preživetje in zmanjšalo obremenjenost organov z vrstami Candida, ugotavljano v intervalu od 24 do 96 ur po zadnjem zdravljenju.
Your doctor may decide to monitor you - for liver function more closely if you develop liver problems during your treatment.
Zdravnik se bo morda odločil, da vas natančneje spremlja: - če se vam med zdravljenjem pojavijo težave z jetri; v tem primeru bo pazljivo spremljal delovanje vaših jeter.
C. parapsilosis harbours an intrinsic alteration in the target gene, which is the likely mechanism for the higher MICs than with other Candida species.
C. parapsilosis ima intrinzično spremembo na tarčnem genu, ki je verjetni mehanizem za večje vrednosti MIK kot pri drugih vrstah Candida.
Additional Data in Neutropenic Patients
Dodatni podatki pri nevtropeničnih bolnikih
(for pH-adjustment), hydrochloric acid (for pH-adjustment)
(za prilagoditev pH), klorovodikova kislina (za prilagoditev pH)
ECALTA should not be given to patients under 18 years of age.
Otroci in mladostniki Zdravila ECALTA ne smejo dobiti bolniki, mlajši od 18 let.
Treatment with ECALTA should be initiated by a physician experienced in the management of invasive fungal infections.
Zdravljenje z zdravilom ECALTA mora uvesti zdravnik, ki ima izkušnje z obvladovanjem invazivnih glivičnih okužb.
As with any overdose, general supportive measures should be utilised as necessary.
Uporabiti je treba splošne podporne ukrepe, kakor je potrebno, tako kot v vsakem primeru prevelikega odmerjanja.
Anidulafungin is not a clinically relevant substrate, inducer, or inhibitor of cytochrome P450 isoenzymes (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A).
Anidulafungin ni klinično pomemben substrat, induktor ali zaviralec izoencimov citokroma P450 (1A2, 2B6, 2C8, 2C9, 2C19, 2D6, 3A).
A standardized technique for testing the susceptibility of Candida species to anidulafungin as well as the respective interpretative breakpoints has been established by European Committee on Antimicrobial Susceptibility Testing (EUCAST).
Stadardizirano tehniko za testiranje občutljivosti vrste Candida na anidulafungin, kot tudi ustrezne mejne vrednosti, je določil Evropski odbor za testiranje občutljivosti na protimikrobna zdravila (EUCAST).
MIC breakpoint (mg/L) ≤S (Susceptible) >R (Resistant)
Mejna vrednost MIK (mg/l) ≤ S (občutljiv) > R (odporen)
Ethnicity Anidulafungin pharmacokinetics were similar among Caucasians, Blacks, Asians, and Hispanics.
Etnična pripadnost Farmakokinetika anidulafungina je pri belcih, črncih, azijcih in hispanih podobna.
Anidulafungin displays linear pharmacokinetics across a wide range of once daily doses (15-130 mg).
Anidulafungin ima linearno farmakokinetiko v širokem razponu odmerkov enkrat na dan (15-130 mg).
The in vitro activity of anidulafungin against Candida species is not uniform.
In vitro aktivnost anidulafungina proti vrstam Candida ni enotna.
No dosing adjustments are required for adult patients based on gender, weight, ethnicity, HIV positivity, or elderly (see section 5.2).
Odmerjanja pri odraslih bolnikih glede na spol, telesno maso, etnično pripadnost, HIV-pozitivnost ali pri starejših bolnikih ni treba prilagajati (glejte poglavje 5.2).
Hypersensitivity to other medicinal products of the echinocandin class.
Preobčutljivost na druga zdravila iz skupine ehinokandinov.
If you are concerned that you may have been given too much ECALTA, tell your doctor or another healthcare professional immediately.
Če vas skrbi, da ste dobili preveč zdravila ECALTA, to nemudoma povejte zdravniku ali drugemu zdravstvenemu delavcu.
Developmental effects observed in rabbits (slightly reduced foetal weights) occurred only at the highest dose tested, a dose that also produced maternal toxicity.
Razvojni učinki, ugotovljeni pri kuncih (rahlo zmanjšanje telesne mase plodov), so se pojavili le pri največjem preskušanem odmerku; ta odmerek je povzročil tudi toksične učinke pri samici materi.
Administration of anidulafungin to rats did not indicate any effects on reproduction, including male and female fertility.
Uporaba anidulafungina pri podganah ni pokazala vplivov na sposobnost razmnoževanja, vključno s plodnostjo samcev in samic.
Additional Data in Patients with Deep Tissue Infections
Dodatni podatki pri bolnikih z okužbami globokega tkiva
Systemic exposure following daily maintenance dose of 0.75 and 1.5 mg/kg/day in this population were comparable to those observed in adults following 50 and 100 mg/day, respectively.
Sistemska izpostavljenost po dnevnem vzdrževalnem odmerku 0,75 oz. 1,5 mg/kg/dan je bila v tej populaciji primerljiva tisti pri odraslih, ki so dobivali 50 mg oz. 100 mg/dan.
Patients in both study arms were permitted to switch to oral fluconazole after at least 10 days of intravenous therapy, provided that they were able to tolerate oral medicinal products and were afebrile for at least 24 hours, and that the most recent blood cultures were negative for Candida species.
Bolniki v obeh krakih preskušanja so lahko po vsaj 10 dneh intravenskega zdravljenja prešli na peroralni flukonazol pod pogoji, da so prenašali peroralno zdravilo, da so bili vsaj 24 ur afebrilni in da so bile najnovejše hemokulture negativne za vrste Candida.
All-cause mortality up to the 6 Week FollowUp visit for anidulafungin (MITT population) was 4/11 (36.4%) and 2/3 (66.7%) for caspofungin.
Umrljivost zaradi vseh razlogov do kontrolnega obiska v 6. tednu je bila 4/11 (36,4 %) za anidulafungin (populacija MITT) in 2/3 (66,7 %) za kaspofungin.
Although weight was identified as a source of variability in clearance in the population pharmacokinetic analysis, weight has little clinical relevance on the pharmacokinetics of anidulafungin.
Čeprav se je telesna masa izkazala kot vir variabilnosti očistka v analizi populacijske farmakokinetike, je njen klinični pomen za farmakokinetiko anidulafungina majhen.
Rate of Successful Global Response a and All-Cause Mortality in Patients with Deep Tissue Candidiasis - Pooled Analysis MITT Population n/N (%)
Delež uspešnega globalnega odziva a in umrljivost zaradi vseh vzrokov pri bolnikih s kandidozo globokega tkiva - analiza združenih podatkov Populacija MITT n/N (%)
Anidulafungin is not dialysable and may be administered without regard to the timing of hemodialysis.
Anidulafungin se ne dializira in ga je mogoče aplicirati ne glede na čas hemodialize.
Specifically, for C. parapsilosis, the MICs of anidulafungin are higher than are those of other Candida species.
Predvsem pri C. parapsilosis so vrednosti MIK za anidulafungin večje kot vrednosti za druge vrste Candida.
The successful global response rate at the end of intravenous treatment (primary endpoint) and end of all treatment and all-cause mortality up to the 6 week follow-up visit is shown in Table 5.
Delež uspešnega globalnega odziva na koncu intravenskega zdravljenja (primarni opazovani dogodek) in na koncu celotnega zdravljenja ter umrljivost zaradi vseh vzrokov do kontrolnega obiska v 6. tednu so prikazani v preglednici 5.
What you need to know before you use ECALTA
Kaj morate vedeti, preden boste uporabili zdravilo ECALTA
Anidulafungin has shown fungicidal activity against Candida species and activity against regions of active cell growth of the hyphae of Aspergillus fumigatus.
Anidulafungin je pokazal fungicidno delovanje proti vrstam Candida ter delovanje proti predelom aktivne celične rasti hif Aspergillus fumigatus.
The infection is caused by fungal cells (yeasts) called Candida.
Okužbo povzročajo glivice (kvasovke), imenovane Candida.
In the clinical trials the outcome for anidulafungin with C. parapsilosis was not statistically different from other species however, the use of echinocandins in candidaemia due to C. parapsilosis may not be regarded as therapy of first choice
V kliničnih preskušanjih se izid za anidulafungin pri C. parapsilosis ni statistično razlikoval od drugih vrst, vendar pa se uporaba ehinokandinov za zdravljenje kandidemije zaradi C.parapsilosis ne more smatrati kot zdravljenje prve izbire.
The population pharmacokinetic analysis showed that median clearance differed slightly between the elderly group (patients ≥ 65, median CL = 1.07 l/h) and the non-elderly group (patients < 65, median CL = 1.22 l/h), however the range of clearance was similar.
Analiza populacijske farmakokinetike je pokazala, da se mediani očistek rahlo razlikuje med starejšo (bolniki ≥ 65 let, mediani očistek = 1,07 l/h) in nestarejšo skupino (bolniki < 65 let, mediani očistek = 1,22 l/h), toda razpon očistkov je bil podoben.
Infusion solution concentration is 0.77 mg/mL
Koncentracija infuzijske raztopine je 0,77 mg/ml.
Dosage adjustments are not required based on HIV positivity, irrespective of concomitant antiretroviral therapy.
Prilagoditev odmerjanja pri HIV-pozitivnih bolnikih ni potrebna, ne glede na sočasno protiretrovirusno zdravljenje.
In general, your treatment should continue for at least 14 days after the last day Candida was found in your blood.
Praviloma boste morali zdravilo dobivati vsaj še 14 dni po dnevu, ko so vam v krvi zadnjič našli Candido.
However, brain concentrations increased in uninfected neonatal rats after five daily doses (brain to plasma ratio of approximately 0.7).
Vendar pa se je koncentracija v možganih pri neokuženih novorojenih podganah po petih dnevnih odmerkih zvišala (razmerje možgani/plazma približno 0,7).
Excipient with known effect: Fructose 102.5 mg per vial
Pomožna(e) snov(i) z znanim učinkom: fruktoza, 102,5 mg na vialo
This results in inhibition of the formation of 1,3--D-glucan, an essential component of the fungal cell wall.
Posledica je zavrtje nastajanja 1,3--D-glukana, nujne sestavine celične stene glivic.
Therefore, no information is available about the penetration of anidulafungin into the cerebrospinal fluid (CSF) and/or across the blood-brain barrier.
Informacij o prehajanju anidulafungina v cerebrospinalni likvor in/ali preko krvno-možganske pregrade zato ni na voljo.
In the primary efficacy analysis, global response in the MITT populations at the end of intravenous therapy, anidulafungin was compared to fluconazole in a pre-specified twostep statistical comparison (non-inferiority followed by superiority).
V primarni analizi učinkovitosti, globalnem odzivu populacij MITT na koncu intravenskega zdravljenja, so anidulafungin primerjali s flukonazolom z vnaprej opredeljeno dvostopenjsko statistično primerjavo (neinferiornosti in zatem superiornosti).
Although a slight decrease in AUC was observed in patients with Child-Pugh C hepatic insufficiency, the decrease was within the range of population estimates noted for healthy subjects.
Čeprav so pri bolnikih z okvaro jeter razreda C po Child-Pughu opazili rahlo zmanjšanje AUC, je bilo to zmanjšanje v območju populacijskih ocen, ugotovljenih pri zdravih preskušancih.
This will be followed by a daily dose of 100 mg (maintenance dose).
Temu sledijo dnevni odmerki po 100 mg (vzdrževalni odmerek).
3 or WBC ≤ 500 cells/mm
≤ 500 celic/mm
The treatment starts with 200 mg on the first day (loading dose).
Zdravljenje se začne z odmerkom 200 mg prvi dan (polnilni odmerek).
Patients were treated for at least 14 days.
Bolnike so zdravili najmanj 14 dni.
Your doctor may prescribe another medicine following your treatment with ECALTA to continue treating your fungal infection or prevent it from returning.
Zdravnik vam lahko po zdravljenju z zdravilom ECALTA predpiše drugo zdravilo, da bi vašo glivično okužbo zdravil naprej oziroma da bi preprečil njeno ponovitev.
If your original symptoms come back, tell your doctor or another healthcare professional immediately.
Če se vam začetni simptomi ponovijo, morate to nemudoma povedati zdravniku ali drugemu zdravstvenemu delavcu.
The pharmacokinetics of anidulafungin after at least 5 daily doses were investigated in 24 immunocompromised paediatric (2 to 11 years old) and adolescent (12 to 17 years old) patients with neutropenia.
Farmakokinetiko anidulafungina po vsaj 5 dnevnih odmerkih so raziskali pri 24 imunsko oslabelih, nevtropeničnih otrocih (starost od 2 do 11 let) in mladostnikih (od 12 do 17 let).
Aseptically reconstitute each vial with 30 mL water for injections to provide a concentration of 3.33 mg/mL.
Aseptično rekonstituirajte vsako vialo s 30 ml vode za injekcije, da dobite koncentracijo 3,33 mg/ml.
In 3 month studies, evidence of liver toxicity, including elevated enzymes and morphologic alterations, was observed in both rats and monkeys at doses 4- to 6-fold higher than the anticipated clinical therapeutic exposure.
V 3-mesečnih študijah so pri podganah in opicah opažali znake toksičnih učinkov na jetra, vključno z zvišanjem encimov in morfološkimi spremembami, pri odmerkih, ki so bili od 4- do 6-krat večji od predvidene klinične terapevtske izpostavljenosti.
There were no adverse reactions in the low-dose animals in the presence or absence of anaesthesia, and no infusion-related reactions in the mid-dose group in the absence of anaesthesia.
V nizkoodmerni skupini živali ni bilo neželenih reakcij ne z anestezijo ne brez nje, v srednjeodmerni skupini pa brez anestezije ni bilo z infundiranjem povezanih reakcij.
The pharmacokinetics of anidulafungin have been characterised in healthy subjects, special populations and patients.
Farmakokinetiko anidulafungina so raziskali pri zdravih osebah, posebnih populacijah in bolnikih.
Some rats in the mid dose group experienced similar reactions but only after administration of anaesthesia.
Pri nekaterih podganah v srednjeodmerni skupini so se pojavile podobne reakcije, vendar šele po uporabi anestezije.
Anidulafungin undergoes slow chemical degradation at physiologic temperature and pH to a ringopened peptide that lacks antifungal activity.
Anidulafungin je pri fiziološki temperaturi in pH podvržen počasni kemični razgradnji v peptid z odprtim obročem, ki nima protiglivičnega delovanja.
The pharmacokinetics of anidulafungin are characterised by a rapid distribution half-life (0.5-1 hour) and a volume of distribution, 30-50 l, which is similar to total body fluid volume.
Za farmakokinetiko anidulafungina sta značilna kratek razpolovni čas porazdelitve (0,5-1 uro) in volumen porazdelitve 30-50 l, kar je podobno celotnemu volumnu tekočine v telesu.
The in vitro degradation half-life of anidulafungin under physiologic conditions is approximately 24 hours.
Razpolovni čas razgradnje anidulafungina v fizioloških razmerah je in vitro približno 24 ur.
Anidulafungin is a semi-synthetic echinocandin, a lipopeptide synthesised from a fermentation product of Aspergillus nidulans.
Anidulafungin je polsintezni ehinokandin, lipopeptid, sintetiziran iz fermentacijskega produkta Aspergillus nidulans.
All patients were treated for at least 14 days.
Vse bolnike so zdravili najmanj 14 dni.
ECALTA must not be administered as a bolus injection.
Zdravila ECALTA se ne sme aplicirati v bolusni injekciji.
It is unknown whether anidulafungin is excreted in human milk.
Ni znano, ali se anidulafungin izloča v materino mleko.
The steady state was achieved on the first day after a loading dose (twice the daily maintenance dose).
Stanje dinamičnega ravnovesja je bilo doseženo prvi dan po polnilnem odmerku (dvakratni dnevni vzdrževalni odmerek).
In vivo, the ring-opened product is subsequently converted to peptidic degradants and eliminated mainly through biliary excretion.
In vivo se produkt z odprtim obročem nato pretvori v peptidne razgradne produkte in izloči pretežno z žolčem.
Patients with increased hepatic enzymes during anidulafungin therapy should be monitored for evidence of worsening hepatic function and evaluated for risk/benefit of continuing anidulafungin therapy.
Bolnike, pri katerih se med zdravljenjem z anidulafunginom pojavi zvišana raven jetrnih encimov, je treba spremljati glede znakov slabšanja delovanja jeter in pri njih oceniti koristi in tveganja nadaljnjega zdravljenja z anidulafunginom.
Anidulafungin exhibited in-vitro activity against C. albicans, C. glabrata, C. parapsilosis, C. krusei and C. tropicalis.
Anidulafungin in vitro deluje proti C. albicans, C. glabrata, C. parapsilosis, C. krusei in C. tropicalis.
There are no data from the use of anidulafungin in pregnant women.
Podatkov o uporabi anidulafungina pri nosečnicah ni.
3 at baseline) with invasive candidiasis was assessed in a prospective, double-blind, randomized, controlled trial.
3 ob izhodišču) z invazivno kandidozo so ocenili v prospektivnem, dvojno slepem, randomiziranem, nadzorovanem preskušanju.
In a clinical study of subjects with mild, moderate, severe or end stage (dialysis-dependent) renal insufficiency, anidulafungin pharmacokinetics were similar to those observed in subjects with normal renal function.
V kliničnem preskušanju s preskušanci z blago, zmerno, hudo ali končno (od dialize odvisno) okvaro ledvic je bila farmakokinetika anidulafungina podobna kot pri preskušancih z normalnim delovanjem ledvic.
What ECALTA is and what it is used for What you need to know before you use ECALTA How to use ECALTA
Kaj je zdravilo ECALTA in za kaj ga uporabljamo Kaj morate vedeti, preden boste uporabili zdravilo ECALTA Kako uporabljati zdravilo ECALTA Možni neželeni učinki
Embryo-foetal development studies were conducted with doses between 0.2- and 2-fold (rats) and between 1- and 4-fold (rabbits) the proposed therapeutic maintenance dose of 100 mg/day.
Embrio-fetalne razvojne študije so bile opravljene z odmerki, ki so bili od 0,2- do 2-kratnik (podgane) oz. od 1- do 4-kratnik (kunci) predvidenega terapevtskega vzdrževalnega odmerka 100 mg/dan.
However, in animal experiments these mutations confer cross resistance to all three echinocandins and therefore such isolates are classified as echinocandin resistant until further clinical experience are obtained concerning anidulafungin.
Vendar so z eksperimenti na živalih pokazali, da te mutacije povzročijo navzkrižno odpornost na vse tri ehinokandine, zato so take izolate do pridobitve dodatnih kliničnih izkušenj z anidulafunginom razvrstili kot odporne proti ehinookandinom..